News - Covidien


Current filters:


Popular Filters

Nuvo's partner Mallinckrodt to resubmit osteoarthritis treatment to US FDA


Canada's Nuvo Research (TSX: NRI) says that its licensing partner Mallinckrodt (NYSE: MNK) has successfully…

Anti-Arthritics/RheumaticsCovidienMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

Covidien to spin out pharma business to Mallinckrodt


Ireland-based health care products group Covidien (NYSE: COV) says that its board of directors has approved…

CovidienMallinckrodtMergers & AcquisitionsPharmaceutical

Covidien files Form 10 registration statement for planned spin-off of Pharma business


Ireland-based medical products and generic drugmaker Covidien (NYSE: COV) has announced the initial filing…

CovidienMallinckrodtMergers & AcquisitionsPharmaceutical

Mallinckrodt to acquire CNS Thera for $100 million; Mediq to sell out for 775 million euros


Mallinckrodt, the soon to be spun-out pharmaceuticals business of Ireland-based Covidien (NYSE: COV),…

CNS TherapeuticsCovidienGenericsMallinckrodtMediqMergers & AcquisitionsPharmaceutical

Covidien to spin off pharmaceuticals business


US medical products and generic drugmaker Covidien (NYSE: COV) says that it plans to spin off its pharmaceuticals…

CovidienGenericsMergers & AcquisitionsNeurologicalPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top